Paper Details

  1. Home
  2. Paper Details

Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.

Author: BhuiyanAbdus Sattar, KobaraHideki, MasakiTsutomu, NakanoDaisuke, NishiyamaAkira, RafiqKazi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Steroidal mineralocorticoid receptor (MR) antagonists have antihypertensive and kidney-protective effects but can have side effects. This study investigated a nonsteroidal MR antagonist, esaxerenone, in diabetic mice. Results show that esaxerenone effectively lowered blood pressure and reduced kidney damage more than spironolactone, suggesting a potential benefit in diabetic kidney disease.
Paper Details　
Original Abstract of the Article :
Although beneficial antihypertensive and antialbuminuric effects of steroidal mineralocorticoid receptor (MR) antagonists have been shown, the use of these drugs has been clinically limited in diabetic kidney disease (DKD) because of the high incidence of side effects. Here, we aimed to examine the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/s41440-019-0211-0

データ提供：米国国立医学図書館（NLM）

A New Hope for Diabetic Kidney Disease: The Rise of Nonsteroidal Mineralocorticoid Receptor Antagonists

The world of kidney disease research is like a vast desert, filled with challenges and mysteries. In the realm of diabetic kidney disease (DKD), researchers are always searching for new oases of hope. This study dives into the exciting potential of a novel nonsteroidal mineralocorticoid receptor (MR) antagonist called esaxerenone.

The study used a high-salt diet to mimic the harsh conditions of DKD in mice. The results show that esaxerenone effectively tackled high blood pressure and improved kidney function, even surpassing the effects of the classic steroidal MR antagonist, spironolactone. This is a significant finding because it offers a potential solution to the side effects associated with steroidal MR antagonists.

Esaxerenone: A Promising New Weapon in the Fight Against DKD

These findings suggest that esaxerenone could be a game-changer in the management of DKD. It provides a new pathway for treating this condition, potentially offering a safer and more effective alternative to existing therapies.

A New Oasis in the Desert of DKD: Hope for a Better Future

The research suggests that esaxerenone may be a valuable tool for managing DKD. It could lead to better treatment outcomes, improved quality of life for patients, and a brighter future for those affected by this complex disease. As a researcher, I am excited about this breakthrough and its potential to improve the lives of countless individuals.

Dr. Camel's Conclusion

This study is a beacon of hope in the desert of DKD research. The discovery of esaxerenone as a potential therapeutic agent for DKD opens up new horizons and offers a promising alternative to existing therapies. As a researcher, I am eager to see further studies explore the potential of this novel drug and its impact on DKD patients.

Date :
  1. Date Completed 2020-09-07
  2. Date Revised 2020-09-07
Further Info :

Pubmed ID

30664703

DOI: Digital Object Identifier

10.1038/s41440-019-0211-0

Related Literature

Article Analysis
・Side Effects of spironolactone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.